China sells coking coal to Indonesia in rare trade, sources say
BEIJING/SINGAPORE, June 16 (Reuters) - China sent a rare shipment of at least three cargoes of coking coal to processors in Indonesia's Sulawesi in May, sources familiar with the matter said, encroaching on a market typically dominated by supplies from Australia and Indonesia.
The world's biggest importer of coking coal, China is not a major exporter of the steelmaking fuel, and has exported it to Indonesia only three times since the start of 2024, monthly Chinese customs data shows.
State-run Shanxi Coking Coal Group (000983.SZ), opens new tab sold coking coal to China Risun Group (1907.HK), opens new tab, which was later exported to Indonesia last month, three sources said. Risun runs one of the largest coke-processing plants in Indonesia's Sulawesi region.
The state-run group sold another cargo to Hong Kong Jinteng Development Ltd for export to Indonesia, the source said, while the second source added that it also sold a third cargo to a Dexin Steel plant in Indonesia.
The sources sought anonymity as they were not authorised to speak on the issue.
Shanxi Coking Coal, China Risun and Dexin Steel did not immediately respond to requests seeking comment. Reuters was unable to reach Hong Kong Jinteng Development Ltd.
Independent consultant Lawrence Yan said the moves were designed to test the economic feasibility of Chinese supply and show traditional sellers, such as Australia, that Indonesian plants had alternatives.
Higher costs and strong competition from Russia and Mongolia made it unlikely the trade would become mainstream, however, he added.
In the longer term, as China's slowing steel industry could free up supply of coking coal, turning it into a regular export product, an executive at Chinese trading house Winsway said last week.
China exported 78,030 metric tons of coking coal to Indonesia in April, the first shipment since last July. Data for May is not available yet.
Coke processing plants in Sulawesi have emerged as a supply hub for metallurgical coke - a raw material used by steelmakers, boosting demand for coking coal, which is used to make the coke.
Indonesia's exports of met coke hit a record high in 2024, according to data from Kpler. However, the region is now struggling with overcapacity, one of the sources said, with utilisation at only 60% to 70%.
Indonesia's met coke exports have also been hit by December's import curbs imposed by major buyer India.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
19 minutes ago
- Reuters
World Bank joins $2.13 bln blended finance package for Indonesia
JAKARTA, June 16 (Reuters) - The World Bank has approved two investments involving a total blended finance package of $2.13 billion to boost economic growth and improve clean energy access across Indonesia, the multinational lender said in a statement on Monday.
Reuters
44 minutes ago
- Reuters
Bank Indonesia to hold rates steady at 5.50% on June 18
BENGALURU, June 16 (Reuters) - Bank Indonesia will hold its interest rate steady on Wednesday, according to two-thirds of economists in a Reuters poll, although they remain divided on where borrowing costs might end the year. Indonesia's central bank will announce its decision just hours before the U.S. Federal Reserve is due to meet, with BI likely to prioritise the stability of the rupiah, which has risen nearly 4% since early April. The Fed is expected to maintain rates until September amid concerns that trade tariffs imposed by U.S. President Donald Trump could fuel inflation in the United States. Of the 31 economists in a June 9-16 Reuters poll, 21 said they expected Bank Indonesia to keep its benchmark seven-day reverse repurchase rate (IDCBRR=ECI), opens new tab unchanged at 5.50% at the conclusion of its two-day meeting. The remaining 10 expected a 25 bps cut to 5.25%, compared to just three economists in May's poll. "BI has limited space to cut, particularly if it wants to maintain some interest rate differential with the U.S., said Lavanya Venkateswaran, senior ASEAN economist at OCBC Bank. The bank cut interest rates by 25 bps to support the slowing economy last month. "Back-to-back rate cuts risk signalling a sense of urgency about the deterioration in the growth outlook, which BI will seek to avoid as it could weigh on broader sentiment and the currency," Venkateswaran added. Some economists warned tensions in the Middle East were fuelling global risk aversion, increasing the likelihood of capital outflows from emerging markets such as Indonesia and putting pressure on the rupiah. Half of respondents who provided a view beyond the upcoming meeting, 14 of 28, expected BI to cut rates to 5.25% by the end of next quarter. Eight forecast rates at 5.00% or below while six saw no change. The median forecast pointed to rates at 5.00% by year-end, but with no majority view. "We still see room for BI to implement further policy rate cuts supported by weakening economic growth, subdued inflation, the potential for a Fed rate cut and Indonesia's relatively sound external sector," said Josua Pardede, chief economist at Permata Bank. (Other stories from the June Reuters global economic poll)
Reuters
an hour ago
- Reuters
Focus: US pharma bets big on China to snap up potential blockbuster drugs
June 16 (Reuters) - U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments. Through June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters. That increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters. "They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig Suvannavejh. The total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData. A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development risks. China's share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in March. Chinese companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and development. While small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. "Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony Ren. The growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America agenda. That has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from database. Roughly a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%. "I think it's only accelerating," Gleason said. The Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical sector. But one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs. "The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare group. In May, Pfizer (PFE.N), opens new tab spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio ( opens new tab. That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is successful. Regeneron Pharmaceuticals (REGN.O), opens new tab in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals ( opens new tab. By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say. U.S.-based drug developer Nuvation Bio (NUVB.N), opens new tab bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week. "We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told Reuters. What makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time." Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry. "It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
